Abstract
Management strategies for acute coronary syndromes (ACS) are making increasing use of both low‐molecular‐weight heparins (LMWHs) and glycoprotein (GP) IIb/IIIa inhibitors. To date, however, relatively few studies have assessed the clinical potential of these two classes of agents in combination. There are theoretical grounds to expect LMWHs to be more effective than unfractionated heparin (UFH) in combination with GP Ilb/IIIa inhibitors, since UFH, but not LMWH, activates platelets. The antiplatelet effects of GP Ilb/IIIa inhibitors are therefore likely to be both more potent and more predictable when combined with LMWH. A recent study in more than 100 patients has demonstrated that a combination of dalteparin and the GP Ilb/IIIa inhibitor abciximab provided effective anticoagulation in patients undergoing percutaneous coronary intervention (PCI), without causing significant bleeding or adverse events. Similar results were demonstrated in the National Investigators Collaborating on Enoxaparin (N1CE‐4) study using a combination of abciximab and enoxaparin in patients undergoing PCI. Of importance is the fact that there were no cases of severe thrombocytopenia in either LMWH study, although this is a recognized potential complication when UFH and abciximab are used in combination. Further studies are now warranted to confirm the efficacy of LMWH and GP Ilb/IIIa inhibitors in combination, both for PCI and medical stabilization.
Keywords: glycoprotein Ilb/IIIa inhibitors; low‐molecular‐weight heparin; dalteparin, abciximab; acute coronary syndrome; percutaneous coronary intervention
Full Text
The Full Text of this article is available as a PDF (398.2 KB).
Reference
- 1. Bertrand ME, Simoons ML, Fox KAA, Wallentin LC, Hamm CW, McFadden E, De Feyter PJ, Specchia G, Ruzyllo W: Management of acute coronary syndromes: Acute coronary syndromes without persistent ST segment elevation. Recommendations of the Task Force of the European Society of Cardiology. Eur Heart J 2000; 21: 1406–1432 [DOI] [PubMed] [Google Scholar]
- 2. Kereiakes DJ, Runyon JP, Broderick TM, Shimshak TM: IIb's are not IIb's. Am J Cardiol 2000; 85: 23C–31C [DOI] [PubMed] [Google Scholar]
- 3. Dunn CJ, Foster RH: Abciximab. A pharmacoeconomic review of its use in percutaneous coronary revascularisation. Pharmacoeconomics 1999; 16: 711–741 [DOI] [PubMed] [Google Scholar]
- 4. Wallentin L, Lagerqvist B, Husted S, Kontny F, Stahle E, Swahn E: Outcome at 1 year after an invasive compared with a non‐invasive strategy in unstable coronary‐artery disease: The FRISCII invasive randomised trial. Lancet 2000; 356: 9–16 [DOI] [PubMed] [Google Scholar]
- 5. Eikelboom JW, Anand SS, Malmberg K, Weitz JI, Ginsberg JS, Yusef S: Unfractionated heparin and low‐molecular‐weight heparin in acute coronary syndrome without ST elevation: A meta‐analysis. Lancet 2000; 355: 1936–1942 [DOI] [PubMed] [Google Scholar]
- 6. Turpie AGG: Can we differentiate the low‐molecular weight heparins? Clin Cardiol 2000; 23 (suppl I): 1–4–1–7 [DOI] [PubMed] [Google Scholar]
- 7. Xiao Z, Theroux P: Platelet activation with unfractionated heparin at therapeutic concentrations and comparisons with a low‐molecular‐weight heparin and with a direct thombin inhibitor. Circulation 1998; 97: 251–256 [DOI] [PubMed] [Google Scholar]
- 8. CAPTURE : Randomized placebo‐controlled trial of abciximab before and during coronary intervention in refractory unstable angina: The CAPTURE study. Lancet 1997; 349: 1429–1435 [PubMed] [Google Scholar]
- 9. PRISM : A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. Platelet Receptor Inhibition in Ischemic Syndrome Management (PRISM). N Engl J Med 1998; 338: 1498–1505 [DOI] [PubMed] [Google Scholar]
- 10. PRISM‐PLUS : Inhibition of platelet glycoprotein Ilb/IIIa receptor with tirofiban in unstable angina and non‐Q‐wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Symptoms and Signs (PRISM‐PLUS) Study Investigators. N Engl J Med 1998; 338: 1488–1497 [DOI] [PubMed] [Google Scholar]
- 11. PARAGON investigators : International, randomized, controlled trial of lamifiban (a platelet glycoprotein inhibitor), heparin, or both in unstable angina. Circulation 1998; 97: 2386–2395 [DOI] [PubMed] [Google Scholar]
- 12. EPILOG investigators : Platelet glycoprotein Ilb/IIIa receptor blockade and low‐dose heparin during percutaneous coronary revascularization. N Engl J Med 1997; 336: 1689–1696 [DOI] [PubMed] [Google Scholar]
- 13. EPISTENT investigators : Randomised placebo‐controlled and bal‐loon‐angioplasty‐controlled trial to assess safety of coronary stenting with the use of platelet glycoprotein Ilb/IIIa blockade. Lancet 1998; 352: 87–92 [DOI] [PubMed] [Google Scholar]
- 14. Cohen M, Theroux P, Weber S, Laramee P, Huynh T, Borzak S, Diodati JG, Squire IB, Deckelbaum LI, Thornton AR, Harris KE, Sax FL, Lo MW, White HD: Combination therapy with tirofiban and enoxaparin in acute coronary syndromes. Int J Cardiol 1999; 71: 273–281 [DOI] [PubMed] [Google Scholar]
- 15. Kereiakes DJ, Fry E, Matthai W, Niederman A, Barr L, Brodie B, Zidar J, Casale P, Christy G, Molitemo D, Lengerich R, Broderick T, Shimshak T, Cohen M: Combination enoxaparin and abciximab therapy during percutaneous coronary intervention: “NICE guys finish first.” J Invas Cardiol 2000; 12 (suppl A): 1A–5A [PubMed] [Google Scholar]
- 16. Kereiakes DJ, Kleiman NS, Fry E, Lengerich R, Aquilina J, DeLoof M, Mwawasi G, Maresh K, Burkhart L, Broderick T: Dalteparin and abciximab combination for percutaneous coronary intervention: First dose finding results (abstr). Transcath Cardiovasc Ther 2000; Washington meeting, Oct.